Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

William Thom

Pain Medicine Jerseyville, IL Medical Doctor

NPI 1225015456 CMS profile 328012

400 Maple Summit Rd, Pain Center, Jerseyville, IL 62052

Open in the dashboard

General payments

$12,593

232 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, William Thom of Jerseyville, IL is reported in the CMS Open Payments database as having received $12,593 across 232 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 84th percentile of Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $659 15
2024 General $1,951 21
2023 General $2,976 40
2022 General $854 14
2021 General $1,947 34
2020 General $476 20
2019 General $3,730 88

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • William Thom
  • Pain Medicine median
  • Middle half of Pain Medicine
  • National median

In program year 2025, general payments to William Thom were reported at $659. Among 2,779 Pain Medicine profiles paid that year, the median was $458 and the middle half received between $124 and $1,401.

Show as a table
Year William Thom Pain Medicine median Middle half National median
2019 $3,730 $498 $126–$1,682 $163
2020 $476 $284 $80–$910 $114
2021 $1,947 $399 $112–$1,219 $132
2022 $854 $455 $137–$1,484 $149
2023 $2,976 $484 $128–$1,495 $160
2024 $1,951 $498 $131–$1,540 $164
2025 $659 $458 $124–$1,401 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $4,437 71 payments
  2. Medtronic USA, Inc. $3,434 80 payments
  3. Relievant Medsystems, Inc. $985 12 payments
  4. SPR Therapeutics, Inc $814 5 payments
  5. Vertos Medical, Inc. $507 11 payments
  6. Nevro Corp. $437 4 payments
  7. TerSera Therapeutics LLC $326 15 payments
  8. Stimwave Technologies Incorporated $302 2 payments
  9. Boston Scientific Corporation $251 2 payments
  10. Trevena, Inc. $196 3 payments
  11. Other $905 27 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $9,642 222 payments
  2. Travel and Lodging $2,950 10 payments
Products named General payments · program years 2019–2025
  1. INTELLIS ADAPTIVESTIM $3,476 50 payments
  2. RESTORE $1,809 45 payments
  3. SYNCHROMED $1,448 9 payments
  4. Intracept Pain $923 10 payments
  5. Intracept Pain $923 10 payments
  6. SPRINT PNS System $814 5 payments
  7. mild Device Kit $507 11 payments
  8. INTELLIS $456 7 payments
  9. PRIALT $326 15 payments
  10. Vyrsa V1 $316 3 payments
  11. Other $2,500 87 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 12 drugs

Part D claims

469

Median for Anesthesiology: 322

Drug cost

$10,949

Median for Anesthesiology: $8,738

Branded share of claims

28.8%

Median for Anesthesiology: 25.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Buprenorphine Generic 21 $3,562
Pregabalin Generic 100 $2,737
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 135 $2,307
Naloxone Hcl Generic 12 $836
Gabapentin Generic 43 $413
Tramadol Hcl Generic 66 $228
Duloxetine Hcl Generic 25 $216
Oxycodone Hcl Generic 13 $204
Tizanidine Hcl Generic 11 $144
Cyclobenzaprine Hcl Generic 12 $117

The 10 drugs with the highest cost, of 12 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,517 Part D prescribers listed as Anesthesiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 61 billing codes

Paid by Medicare

$112,215

Of which drugs: $468

Medicare patients

254

Average age 73

Services billed

1,320

163 women, 91 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 30%
Depression 29%
Ischemic heart disease 26%
COPD 22%
Atrial fibrillation 19%
Chronic kidney disease 19%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 19 116 $85

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

232 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record